ArticleJournal of natural medicines2026
Monocarpinensis A-B: two novel cycloartane triterpenoids isolated from Monocarpia kalimantanensis and their medicinal evaluation.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Monocarpia kalimantanensis (Annonaceae) is often used by indigenous communities in East Kalimantan, Indonesia, but information on its chemical composition and biological activity remains limited. Therefore, this study aims to isolate two new monocarpin derivatives from n-hexane extracts of M. kalimantanensis bark, namely monocarpinensis A (1) and monocarpinensis B (2), as well as one known cycloartane-type triterpenoid (3). The structures of these new compounds were determined through comprehensive spectroscopic analysis, including HRTOF-MS, 1D and 2D NMR, IR, UV, and ECD, supported by TD-DFT calculations. All isolated compounds were tested for ex vivo antiplasmodial activity, and compounds 1–3 were evaluated against MCF-7 and normal CV-1 cell lines using PrestoBlue method. The cytotoxicity assay showed that monocarpinensis A (1) had the lowest IC₅₀ values of 126.5 and 520.2 µM against MCF-7 and CV-1 cell lines, respectively. However, compounds 1–3 did not show significant antiplasmodial activity. The current study is the first to report monocarpin derivatives from M. kalimantanensis and their evaluations as potential anticancer and antiplasmodial candidates.
Indexed as
Identifiers
41963766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.